Compare Piramal Enterprises with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs AJANTA PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES AJANTA PHARMA PIRAMAL ENTERPRISES/
AJANTA PHARMA
 
P/E (TTM) x -48.9 24.7 - View Chart
P/BV x 1.6 6.9 24.0% View Chart
Dividend Yield % 1.4 0.5 274.1%  

Financials

 PIRAMAL ENTERPRISES   AJANTA PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
AJANTA PHARMA
Mar-19
PIRAMAL ENTERPRISES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3031,422 232.3%   
Low Rs1,797898 200.2%   
Sales per share (Unadj.) Rs716.5233.5 306.8%  
Earnings per share (Unadj.) Rs79.744.0 181.3%  
Cash flow per share (Unadj.) Rs107.952.2 206.9%  
Dividends per share (Unadj.) Rs28.009.00 311.1%  
Dividend yield (eoy) %1.10.8 141.5%  
Book value per share (Unadj.) Rs1,477.5255.1 579.2%  
Shares outstanding (eoy) m184.4588.02 209.6%   
Bonus/Rights/Conversions ISBB-  
Price / Sales ratio x3.65.0 71.7%   
Avg P/E ratio x32.026.4 121.3%  
P/CF ratio (eoy) x23.622.2 106.3%  
Price / Book Value ratio x1.74.5 38.0%  
Dividend payout %35.120.5 171.6%   
Avg Mkt Cap Rs m470,292102,081 460.7%   
No. of employees `0007.86.8 115.0%   
Total wages/salary Rs m22,5044,307 522.5%   
Avg. sales/employee Rs Th16,899.43,022.6 559.1%   
Avg. wages/employee Rs Th2,877.7633.4 454.3%   
Avg. net profit/employee Rs Th1,879.9569.1 330.4%   
INCOME DATA
Net Sales Rs m132,15320,554 643.0%  
Other income Rs m3,128211 1,483.9%   
Total revenues Rs m135,28120,765 651.5%   
Gross profit Rs m66,2905,664 1,170.3%  
Depreciation Rs m5,202721 721.6%   
Interest Rs m44,09712 380,150.0%   
Profit before tax Rs m20,1195,143 391.2%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,6111,273 676.5%   
Profit after tax Rs m14,7013,870 379.9%  
Gross profit margin %50.227.6 182.0%  
Effective tax rate %42.824.8 172.9%   
Net profit margin %11.118.8 59.1%  
BALANCE SHEET DATA
Current assets Rs m122,74211,812 1,039.1%   
Current liabilities Rs m310,8103,776 8,230.3%   
Net working cap to sales %-142.339.1 -364.0%  
Current ratio x0.43.1 12.6%  
Inventory Days Days2377 29.8%  
Debtors Days Days3982 47.6%  
Net fixed assets Rs m116,90414,398 811.9%   
Share capital Rs m369175 210.3%   
"Free" reserves Rs m272,16122,277 1,221.7%   
Net worth Rs m272,53022,452 1,213.8%   
Long term debt Rs m270,1967 4,093,881.8%   
Total assets Rs m856,26126,962 3,175.8%  
Interest coverage x1.5444.3 0.3%   
Debt to equity ratio x1.00 337,269.8%  
Sales to assets ratio x0.20.8 20.2%   
Return on assets %6.914.4 47.7%  
Return on equity %5.417.2 31.3%  
Return on capital %12.423.0 54.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20010,682 142.3%   
Fx outflow Rs m4,8892,102 232.6%   
Net fx Rs m10,3128,580 120.2%   
CASH FLOW
From Operations Rs m-115,9753,748 -3,094.5%  
From Investments Rs m-8,265-2,228 371.0%  
From Financial Activity Rs m107,525-1,475 -7,291.8%  
Net Cashflow Rs m-16,65045 -36,836.7%  

Share Holding

Indian Promoters % 52.9 73.8 71.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 1.6 258.1%  
FIIs % 26.6 7.6 350.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 17.0 97.1%  
Shareholders   93,274 20,968 444.8%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Surged 1,147 Points Today(Closing)

Indian share markets continued their momentum and ended their day on a strong note today.

Related Views on News

PIRAMAL ENTERPRISES at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Mar 3, 2021 | Updated on Mar 3, 2021

PIRAMAL ENTERPRISES share price has hit a 52-week high. It is presently trading at Rs 1,969. BSE 500 Index is up by 0.9% at 20,109. Within the BSE 500, PIRAMAL ENTERPRISES (up 2.6%) and IFCI (up 11.8%) are among the top gainers, while top losers are IRCON INTERNATIONAL and MMTC.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

I Believe the Investment of the Year Will Be...

Feb 19, 2021

In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Mar 3, 2021 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS